Clinical trials: Refractory T-Cell Lymphoma
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
This clinical trial studies fludarabine phosphate and total-body radiation followed by donor peripheral blood stem cell transplant and immunosuppression in treating patients with hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00014235
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 160 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
RATIONALE: Cyproheptadine hydrochloride may help improve appetite and lessen weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine hydrochloride is more effective with or without nutritional…
- Conditions
- Leukemia, Lymphoma, Malnutrition, Myelodysplastic Syndromes
- Trial name
- NCT00949117
- Testing
- Ensure, PediaSure, cyproheptadine hydrochloride
- Volunteers
- 9 people
- Sponsor
- University of South Florida
Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia
CAR T Cell Therapy Related Cardiovascular Outcomes
This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies.
- Conditions
- Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- CARTCO (NCT05130489)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College London Hospitals
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
- Trial name
- 24CT015 (NCT06934382)
- Testing
- Allogeneic anti-CD7 CAR-T cells (BEAM-201)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Stephan Grupp MD PhD
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy
- Trial name
- NCT04227015
- Testing
- CTA101
- Where
- China
- Volunteers
- 72 people
- Sponsor
- He Huang
Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
Traditional salvage chemotherapy has low efficacy and poor long-term prognosis for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
- Conditions
- Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
- Trial name
- NCT06581081
- Testing
- Senl_B19 autologous CAR-T (S1904) treatment
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University People's Hospital
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005092
- Testing
- Cyclophosphamide, Psoralen, Thiotepa
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
This phase I trial is studying the side effects and best dose of flavopiridol in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00101231
- Testing
- alvocidib
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma Leukemia
Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
B cell malignancies comprise a heterogeneous group of neoplasms including a vast majority of non-Hodgkin's lymphomas (NHL), lymphoblastic leukemias (ALL) and chronic lymphocytic leukemias (CLL).
- Trial name
- NCT03811457
- Testing
- Welgenaleucel
- Where
- China
- Volunteers
- 9 people
- Sponsor
- UWELL Biopharma
T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
This is a multi-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies.
- Conditions
- T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
- Trial name
- nanobody CD5 (NCT07070323)
- Testing
- Autologous CD5 CAR T-cells, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells, Newly matched donor-derived CD5 CAR T-cells
- Where
- 4 sites in China
- Volunteers
- 54 people
- Sponsor
- Beijing GoBroad Hospital
Leukemia, Lymphoma
The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies
PACMAN is a phase I/II single arm, open-label, multi-center study evaluating the safety of human CD19 CAR-T (huCAR19) produced locally using the Miltenyi Prodigy in children, adolescents and young adults with relapsed/refractory…
- Trial name
- PACMAN (NCT07020260)
- Testing
- CAR T-cell and Cellular Therapies
- Where
- 2 sites in Netherlands
- Volunteers
- 18 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Anaplastic Large-Cell Lymphoma
Denileukine Diftitox for Relapsed ALCL
The purpose of this study is to determine is Denileukin diftitox will be safe, well tolerated and induce a significant overall response alone and in combination with chemotherapy: ifosfamide, carboplatin and etoposide (ICE) and…
- Trial name
- NCT00801918
- Testing
- Denileukin Diftitox, Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Columbia University
T Cell Lymphoma, T Cell Leukemia
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies.
- Conditions
- T Cell Lymphoma, T Cell Leukemia, T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoma of CNS
- Trial name
- BAH246 (NCT06420076)
- Testing
- CD5/CD7 CAR-T
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Essen Biotech
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and…
- Conditions
- B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma
- Trial name
- NCT04088864
- Testing
- Fludarabine, Cyclophosphamide, Autologous CD22 CAR T
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kara Lynn Davis
CD19-ALL, CD19-LNH
Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL
The primary objective of this phase I study is to evaluate the safety and to establish the recommended dose of CD19-CART01 infused in pediatric patients affected by relapsed/refractory B-ALL or NHL with measurable Bone Marrow…
- Trial name
- NCT03373071
- Testing
- CD19-CAR T cell
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
CD19 Positive, CD22 Positive
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia…
- Conditions
- CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease
- Trial name
- NCT04029038
- Testing
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
Relapsed or refractory acute leukemia (R/R AL) is a life-threatening blood cancer with poor outcomes and limited treatment options.
- Conditions
- Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Trial name
- R/R AL (NCT07696481)
- Testing
- PID23 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhujiang Hospital
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoma
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
RATIONALE: Giving chemotherapy drugs, such as fludarabine and melphalan, before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00008307
- Testing
- anti-thymocyte globulin, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
CAR-T Cell Therapy, Lymphomas
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
evaluate the safety and Esfficacy of CAR-T technology for the treatment of recurrent/refractory malignant hematological lymphomas
- Trial name
- CAR-T Therapy (NCT06647329)
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mingzhi Zhang